Abstract:Background: Although the diagnosis and treatment of glioblastoma (GBM) is significantly improved with recent progresses, there is still a large heterogeneity in therapeutic effects and overall survival. The aim of this study is to analyze gene expressions of transcription factors (TFs) in GBM so as to discover new tumor markers. Methods: Differentially expressed TFs are identified by data mining using public databases. The GBM transcriptome profile is downloaded from The Cancer Genome Atlas (TCGA). The nonnegative matrix factorization (NMF) method is used to cluster the differentially expressed genes to discover hub genes and signal pathways. The TFs affecting the prognosis of GBM are screened by univariate and multivariate COX regression analysis, and the receiver operating characteristic (ROC) curve is determined. The GBM hazard model and nomogram map are constructed by integrating the clinical data. Finally, the TFs involving potential signaling pathways in GBM are screened by Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Results: There are 68 differentially expressed TFs in GBM, of which 43 genes are upregulated and 25 genes are downregulated. NMF clustering analysis suggested that GBM patients are divided into three groups: Clusters A, B, and C. LHX2, MEOX2, SNAI2, and ZNF22 are identified from the above differential genes by univariate/multivariate regression analysis. The risk score of those four genes are calculated based on the beta coefficient of each gene, and we found that the predictive ability of the risk score gradually increased with the prolonged predicted termination time by time-dependent ROC curve analysis. The nomogram results have showed that the integration of risk score, age, gender, chemotherapy, radiotherapy, and 1p/19q can further improve predictive ability towards the survival of GBM. The pathways in cancer, phosphoinositide 3-kinases (PI3K)-Akt signaling, Hippo signaling, and proteoglycans, are highly enriched in high-risk groups by GSEA. These genes are mainly involved in cell migration, cell adhesion, epithelial-mesenchymal transition (EMT), cell cycle, and other signaling pathways by GO and KEGG analysis. Conclusion: The four-factor combined scoring model of LHX2, MEOX2, SNAI2, and ZNF22 can precisely predict the prognosis of patients with GBM.

Predictive Model to Identify the Long Time Survivor in Patients with Glioblastoma: A Cohort Study Integrating Machine Learning Algorithms

The Potential of DEirlncRNAs: A Novel Approach to Predict Glioblastoma Prognosis

Comprehensive Molecular Characterization of Long-Term Glioblastoma Survivors

AB047. Searching for Factors Relating to Long-Term Survivors of Glioblastoma

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma

An online survival predictor in glioma patients using machine learning based on WHO CNS5 data

Identification of an Immune-Related Prognostic Signature for Glioblastoma by Comprehensive Bioinformatics and Experimental Analyses

Integrated Analysis of Single‐cell RNA‐seq Dataset and Bulk RNA‐seq Dataset Constructs a Prognostic Model for Predicting Survival in Human Glioblastoma

Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients

Predictive Analyses of Prognostic-Related Immune Genes and Immune Infiltrates for Glioblastoma

A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients with GBM.

A 5‐gene Prognostic Nomogram Predicting Survival Probability of Glioblastoma Patients

Development and validation of a nomogram to predict overall survival in patients with glioma: a population-based study

Nimg-59. Comparative Analysis Of Long-Term Glioblastoma Survivors Using Machine Learning Generated Radio-Pathomic Metrics

Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics

Prognostic evaluation of patients with glioblastoma using a new score prediction model.

Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients

EPCO-24. MACHINE LEARNING ALGORITHMS UTILIZING TRANSCRIPTIONAL SIGNATURES PREDICT SURVIVAL OUTCOMES IN GLIOMA

Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma

An Immune-Related Gene Pairs Signature for Predicting Survival in Glioblastoma

Machine learning classifiers for predicting 3-year progression-free survival and overall survival in patients with gliomas after surgery.